/
Hematology
Hemolytic Anemia
19
Pipeline Programs↗
26
Active Trials↗
15
Companies Involved↗
Hemolytic Anemia is an emerging landscape with 19 programs across 15 companies. The most active players are Rigel Pharmaceuticals, China Immunotech (Beijing) Biotechnology Co., Ltd., Novartis. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 17
Phase 36
Approved
No programs
Analysis
Modality Breakdown
67%
Small molecule
10 of 15 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 95% of 19 pipeline programs.
Analysis
Trial Status
50
clinical trials
Completed12 · 24%
Not yet recruiting11 · 22%
Active, not recruiting8 · 16%
Recruiting6 · 12%
Terminated5 · 10%
Unknown status4 · 8%
Other4 · 8%
Clinical Trials
Trial Activity
50 trials
CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06212154·13 enrolled
Second-line Treatment of Primary Autoimmune Hemolytic Anemia
Recruiting·—·Phase 3·NCT05057468·30 enrolled
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia
Active, not recruiting·National Heart, Lung, and Blood Institute (NHLBI)·Preclinical·NCT00061568·130 enrolled
The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04398459·18 enrolled
CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06231368·6 enrolled
A Phase 1 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of F182112 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07816341·12 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)